Modality
Nanobody
MOA
AuroraAi
Target
PARP
Pathway
DDR
SLEThymomaACC
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
Feb 2018
→ Jan 2028
Phase 2Current
NCT04158192
2,869 pts·SLE
2018-02→2028-01·Terminated
2,869 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-064mo agoEMA Filing· ACC
2028-01-041.8y awayPh2 Data· SLE
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2
Termina…
Catalysts
EMA Filing
2025-12-06 · 4mo ago
ACC
Ph2 Data
2028-01-04 · 1.8y away
SLE
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04158192 | Phase 2 | SLE | Terminated | 2869 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| ILM-2412 | Illumina | Phase 3 | PLK4 |